/
Oncology
Metastatic Solid Tumors
234
Pipeline Programs↗
192
Active Trials↗
147
Companies Involved↗
Metastatic Solid Tumors is a highly competitive landscape with 234 programs across 147 companies. The most active players are TScan Therapeutics, Inc., Merck & Co., Egle Therapeutics. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical13
Phase 1136
Phase 284
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
181 of 199 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 199 classified programs, each share of the total. Modality classified for 94% of 234 pipeline programs.
Analysis
Trial Status
477
clinical trials
Completed175 · 37%
Recruiting134 · 28%
Terminated67 · 14%
Active, not recruiting37 · 8%
Unknown status31 · 6%
Not yet recruiting20 · 4%
Other13 · 3%
Clinical Trials
Trial Activity
477 trials
Page 1 of 32
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)